Redirecting T lymphocyte specificity using T cell receptor genes

International Reviews of Immunology

Volumn 22, Issue 3-4, 2003, Pages 229-253

  Kaplan, Barbara L F ^a   Yu, David C ^a   Clay, Timothy M ^b   Nishimura, Michael I ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cytotoxic T lymphocytes; Gene therapy; Immunotherapy; T cell receptor

Indexed keywords

CD3 ANTIGEN; FC RECEPTOR; IMMUNOGLOBULIN; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CELL SPECIFICITY; CELL TRANSFER; CHIMERA; CYTOTOXIC T LYMPHOCYTE; GENE THERAPY; HUMAN; IMMUNE RESPONSE; PERIPHERAL LYMPHOCYTE; RECEPTOR GENE; RETROVIRUS; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE RECEPTOR GENE; TUMOR IMMUNITY;

HUMANS; JURKAT CELLS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TRANSFECTION;

EID: 0037937404     PISSN: 08830185     EISSN: None     Source Type: Journal    
DOI: 10.1080/08830180305227     Document Type: Review

References (120)

1. M.B. Atkins, M.T. Lotze, J.P. Dutcher, R.I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, C. Paradise, L. Kunkel, and S.A. Rosenberg, High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol., 17: 2105-2116, 1999.
2. R.A. Clynes, T.L. Towers, L.G. Presta, and J.V. Ravetch, Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med., 6: 443-446, 2000.
3. K. Fujio, Y. Misaki, K. Setoguchi, S. Morita, K. Kawahata, I. Kato, T. Nosaka, K. Yamamoto, and T. Kitamura, Functional reconstitution of class II MHC-restricted T cell immunity mediated by retroviral transfer of the alpha beta TCR complex. J. Immunol., 165: 528-532, 2000.
4. G. Fyfe, R.I. Fisher, S.A. Rosenberg, M. Sznol, D.R. Parkinson, and A.C. Louie, Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol., 13: 688-696, 1995.
5. R.T. Reilly, J.P. Machiels, L.A. Emens, A.M. Ercolini, F.I. Okoye, R.Y. Lei, D. Weintraub, and E.M. Jaffee, The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res., 61: 880-883, 2001.
6. S.A. Rosenberg, Progress in human tumour immunology and immunotherapy. Nature, 411: 380-384, 2001.
7. S.A. Rosenberg, M.T. Lotze, L.M. Muul, S. Leitman, A.E. Chang, S.E. Ettinghausen, Y.L. Matory, J.M. Skibber, E. Shiloni, J.T. Vetto, C.A. Seipp, C. Simpson, and C.H. Reichert, Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med., 313: 1485-1492, 1985.
8. S.A. Rosenberg, J.C. Yang, D.E. White, and S.M. Steinberg, Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response, Ann. Surg., 228: 307-319, 1998.
9. T. Boon, and L.J. Old, Cancer tumor antigens. Curr. Opin. Immunol., 9: 681-683, 1998.
10. S.A. Rosenberg, A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity, 10: 281-287, 1999.
11. M.J. Glennie, and P.W. Johnson, Clinical trials of antibody therapy. Immunol. Today, 21: 403-410, 2000.
12. S. Menard, E. Tagliabue, M. Campiglio, and S.M. Pupa, Role of HER2 gene overexpression in breast carcinoma. J. Cell. Physiol., 182: 150-162, 2000.
13. J. Baselga, D. Tripathy, J. Mendelsohn, S. Baughman, C.C. Benz, L. Dantis, N.T. Sklarin, A.D. Seidman, C.A. Hudis, J. Moore, P.P. Rosen, T. Twaddell, I.C. Henderson, and L. Norton, Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neuoverexpressing metastatic breast cancer. J. Clin. Oncol., 14: 737-744, 1996.
14. M.A. Cobleigh, C.L. Vogel, D. Tripathy, N.J. Robert, S. Scholl, L. Fehrenbacher, J.M. Wolter, V. Paton, S. Shak, G. Lieberman, and D.J. Slamon, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol., 17: 2639-2648, 1999.
15. J. Stebbing, E. Copson, and S. O'Reilly, Herceptin (trastuzamab) in advanced breast cancer. Cancer Treat. Rev., 26: 287-290, 2000.
16. C.A. White, R.L. Weaver, and A.J. Grillo-Lopez, Antibody-targeted immunotherapy for treatment of malignancy. Annu. Rev. Med., 52: 125-145, 2001.
17. M. Balzar, M.J. Winter, C.J. de Boer, and S.V. Litvinov, The biology of the 17-1A antigen (Ep-CAM). J. Mol. Med., 77: 699-712, 1999.
18. G. Riethmuller, E. Holz, G. Schlimok, W. Schmiegel, R. Raab, K. Hoffken, R. Gruber, I. Funke, H. Pichlmaier, H. Hirche, P. Buggisch, J. Witte, and R. Pichlmayr, Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial. J. Clin. Oncol., 16: 1788-1794, 1998.
19. J.K. Riley and M.X. Sliwkowski, CD20: A gene in search of a function. Semin. Oncol., 27: 17-24, 2000.
20. B. Coiffier, C. Haioun, N. Ketterer, A. Engert, H. Tilly, D. Ma, P. Johnson, A. Lister, M. Feuring-Buske, J.A. Radford, R. Capdeville, V. Diehl, and F. Reyes, Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood, 92: 1927-1932, 1998.
21. P.W. Johnson, The therapeutic use of antibodies for malignancy. Transfus. Clin. Biol., 8: 255-259, 2001.
22. S.M. O'Brien, H. Kantarjian, D.A. Thomas, F.J. Giles, E.J. Freireich, J. Cortes, S. Lerner, and M.J. Keating, Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol., 19: 2165-2170, 2001.
23. M.S. Kaminski, J. Estes, K.R. Zasadny, I.R. Francis, C.W. Ross, M. Tuck, D. Regan, S. Fisher, J. Gutierrez, S. Kroll, R. Stagg, G. Tidmarsh, and R.L. Wahl, Radioimmunotherapy with iodine (131) I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood, 96: 1259-1266, 2000.
24. S.Y. Liu, J.F. Eary, S.H. Petersdorf, P.J. Martin, D.G. Maloney, F.R. Appelbaum, D.C. Matthews, S.A. Bush, L.D. Durack, D.R. Fisher, T.A. Gooley, I.D. Bernstein, and O.W. Press, Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J. Clin. Oncol., 16: 3270-3278, 1998.
25. O.W. Press, Radiolabeled antibody therapy of B-cell lymphomas. Semin. Oncol., 26: 58-65, 1999.
26. O.W. Press, J.F. Eary, F.R. Appelbaum, P.J. Martin, W.B. Nelp, S. Glenn, D.R. Fisher, B. Porter, D.C. Matthews, T. Gooley, et al., Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet, 346: 336-340, 1995.
27. R.L. Wahl, K.R. Zasadny, D. MacFarlane, I.R. Francis, C.W. Ross, J. Estes, S. Fisher, D. Regan, S. Kroll, and M.S. Kaminski, Iodine-131 anti-B1 antibody for B-cell lymphoma: An update on the Michigan Phase I experience. J. Nucl. Med., 39: 21S-27S, 1998.
28. L. Nitschke, H. Floyd, and P.R. Crocker, New functions for the sialic acid-binding adhesion molecule CD22, a member of the growing family of Siglecs. Scand. J. Immunol., 53: 227-234, 2001.
29. M.E. Juweid, E. Stadtmauer, G. Hajjar, R.M. Sharkey, S. Suleiman, S. Luger, L.C. Swayne, A. Alavi, and D.M. Goldenberg, Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin. Cancer. Res., 5: 3292s-3303s, 1999.
30. R.M. Sharkey, T.M. Behr, M.J. Mattes, R. Stein, G.L. Griffiths, L.B. Shih, H.J. Hansen, R.D. Blumenthal, R.M. Dunn, M.E. Juweid, and D.M. Goldenberg, Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol. Immunother., 44: 179-188, 1997.
31. S.A. Rosenberg, B.S. Packard, P.M. Aebersold, D. Solomon, S.L. Topalian, S.T. Toy, P. Simon, M.T. Lotze, J.C. Yang, C.A. Seipp, C. Simpson, C. Carter, S. Brock, D. Schwartzentruber, J.P. Wei, and D.E. White, Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med., 319: 1676-1680, 1988.
32. P. Aebersold, C. Hyatt, S. Johnson, K. Hines, L. Korcak, M. Sanders, M. Lotze, S. Topalian, J. Yang, and S.A. Rosenberg, Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: Association with clinical response. J. Natl. Cancer. Inst., 83: 932-937, 1991.
33. F. Arienti, F. Belli, L. Rivoltini, C. Gambacorti-Passerini, L. Furlan, L. Mascheroni, A. Prada, M. Rizzi, E. Marchesi, M. Vaglini, et al., Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2. Cancer Immunol. Immunother., 36: 315-322, 1993.
34. P.J. Bjorkman, M.A. Saper, B. Samraoui, W.S. Bennett, J.L. Strominger, and D.C. Wiley, The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature, 329: 512-518, 1987.
35. O. Rotzschke, K. Falk, K. Deres, H. Schild, M. Norda, J. Metzger, G. Jung, and H.G. Rammensee, Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature, 348: 252-254, 1990.
36. Y. Kawakami, S. Eliyahu, K. Sakaguchi, P.F. Robbins, L. Rivoltini, J.R. Yannelli, E. Appella, and S.A. Rosenberg, Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med., 180: 347-352, 1994.
37. S.L. Topalian, L. Rivoltini, M. Mancini, N.R. Markus, P.F. Robbins, Y. Kawakami, and S.A. Rosenberg, Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA, 91: 9461-9465, 1994.
38. C.E. Touloukian, W.W. Leitner, S.L. Topalian, Y.F. Li, P.F. Robbins, S.A. Rosenberg, and N.P. Restifo, Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J. Immunol., 164: 3535-3542, 2000.
39. H.M. Zarour, J.M. Kirkwood, L.S. Kierstead, W. Herr, V. Brusic, C.L. Slingluff, Jr., J. Sidney, A. Sette, and W.J. Storkus, Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc. Natl. Acad. Sci. USA, 97: 400-405, 2000.
40. B.S. Wilson, G. Ruberto, and S. Ferrone, Immunochemical characterization of a human high molecular weight-melanoma associated antigen identified with monoclonal antibodies. Cancer Immunol. Immunother., 14: 196-201, 1983.
41. C.C. Harris and M. Hollstein, Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med., 329: 1318-1327, 1993.
42. T.K. Hoffmann, K. Nakano, E.M. Elder, G. Dworacki, S.D. Finkelstein, E. Appella, T.L. Whiteside, and A.B. DeLeo, Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: Implications for immunoselection of epitope loss variants. J. Immunol., 165: 5938-5944, 2000.
43. A. Jansson, M. Gentile, and X.F. Sun, p53 mutations are present in colorectal cancer with cytoplasmic p53 accumulation. Int. J. Cancer., 92: 338-341, 2001.
44. A.M. Barfoed, T.R. Petersen, A.F. Kirkin, P. Thor Straten, M.H. Claesson, and J. Zeuthen, Cytotoxic T-lymphocyte clones, established by stimulation with the HLA- A2 binding p5365-73 wild type peptide loaded on dendritic cells in vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand. J. Immunol., 51: 128-133, 2000.
45. J.G. Houbiers, H.W. Nijman, S.H. van der Burg, J.W. Drijfhout, P. Kenemans, C.J. van de Velde, A. Brand, F. Momburg, W.M. Kast, and C.J. Melief, In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol., 23: 2072-2077, 1993.
46. D.B. Agus, P.A. Bunn, Jr., W. Franklin, M. Garcia, and R.F. Ozols, HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin. Oncol., 27: 53-63; discussion 92-100, 2000.
47. M.L. Disis, J.W. Smith, A.E. Murphy, W. Chen, and M.A. Cheever, In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res., 54: 1071-1076, 1994.
48. B. Fisk, T.L. Blevins, J.T. Wharton, and C.G. Ioannides, Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med., 181: 2109-2117, 1995.
49. C.G. Ioannides, B. Fisk, D. Fan, W.E. Biddison, J.T. Wharton, and C.A. O'Brian, Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol., 151: 225-234, 1993.
50. I. Yoshino, P.S. Goedegebuure, G.E. Peoples, A.S. Parikh, J.M. DiMaio, H.K. Lyerly, A.F. Gazdar, and T.J. Eberlein, HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res., 54: 3387-3390, 1994.
51. L.H. Butterfield, A. Koh, W. Meng, C.M. Vollmer, A. Ribas, V. Dissette, E. Lee, J.A. Glaspy, W.H. McBride, and J.S. Economou, Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res., 59: 3134-3142, 1999.
52. L.H. Butterfield, W.S. Meng, A. Koh, C.M. Vollmer, A. Ribas, V.B. Dissette, K. Faull, J.A. Glaspy, W.H. McBride, and J.S. Economou, T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J. Immunol., 166: 5300-5308, 2001.
53. S.E. Alters, J.R. Gadea, and R. Philip, Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells. Adv. Exp. Med. Biol., 417: 519-524, 1997.
54. E. Ras, S.H. van der Burg, S.T. Zegveld, R.M. Brandt, P.J. Kuppen, R. Offringa, S.O. Warnarr, C.J. van de Velde, and C.J. Melief, Identification of potential HLA-A *0201 restricted CTL epitopes derived from the epithelial cell adhesion molecule (Ep-CAM) and the carcinoembryonic antigen (CEA). Hum. Immunol., 53: 81-89, 1997.
55. P. Correale, K. Walmsley, C. Nieroda, S. Zaremba, M. Zhu, J. Schlom, and K.Y. Tsang, In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl. Cancer. Inst., 89: 293-300, 1997.
56. B.H. Xue, Y. Zhang, J.A. Sosman, and D.J. Peace, Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate, 30: 73-78, 1997.
57. E. Jager, Y.T. Chen, J.W. Drijfhout, J. Karbach, M. Ringhoffer, D. Jager, M. Arand, H. Wada, Y. Noguchi, E. Stockert, L.J. Old, and A. Knuth, Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med., 187: 265-270, 1998.
58. M. Bocchia, V. Bronte, M.P. Colombo, A. De Vincentiis, M. Di Nicola, G. Forni, L. Lanata, R.M. Lemoli, M. Massaia, D. Rondelli, P. Zanon, and S. Tura, Antitumor vaccination: Where we stand. Haematologica, 85: 1172-1206, 2000.
59. F. Arienti, J. Sule-Suso, F. Belli, L. Mascheroni, L. Rivoltini, C. Melani, M. Maio, N. Cascinelli, M.P. Colombo, and G. Parmiani, Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum. Gene Ther., 7: 1955-1963, 1996.
60. N.G. Chakraborty, J.R. Sporn, A.F. Tortora, S.H. Kurtzman, H. Yamase, M.T. Ergin, and B. Mukherji, Immunization with a tumor-cell-lysate-loaded autologousantigen-presenting-cell-based vaccine in melanoma. Cancer Immunol. Immunother., 47: 58-64, 1998.
61. M. Marchand, N. van Baren, P. Weynants, V. Brichard, B. Dreno, M.H. Tessier, E. Rankin, G. Parmiani, F. Arienti, Y. Humblet, A. Bourlond, R. Vanwijck, D. Lienard, M. Beauduin, P.Y. Dietrich, V. Russo, J. Kerger, G. Masucci, E. Jager, J. De Greve, J. Atzpodien, F. Brasseur, P.G. Coulie, P. van der Bruggen, and T. Boon, Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA- A1. Int. J. Cancer, 80: 219-230, 1999.
62. P. Moller, Y. Sun, T. Dorbic, S. Alijagic, A. Makki, K. Jurgovsky, M. Schroff, B.M. Henz, B. Wittig, and D. Schadendorf, Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: A clinical phase I study. Br. J. Cancer, 77: 1907-1916, 1998.
63. D.L. Morton, L.J. Foshag, D.S. Hoon, J.A. Nizze, L.A. Wanek, C. Chang, D.G. Davtyan, R.K. Gupta, R. Elashoff, and R.F. Irie, Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg., 216: 463-482, 1992.
64. F.O. Nestle, S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf, Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
65. S.A. Rosenberg, J.C. Yang, D.J. Schwartzentruber, P. Hwu, F.M. Marincola, S.L. Topalian, N.P. Restifo, M.E. Dudley, S.L. Schwarz, P.J. Spiess, J.R. Wunderlich, M.R. Parkhurst, Y. Kawakami, C.A. Seipp, J.H. Einhorn, and D.E. White, Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-327, 1998.
66. R. Soiffer, T. Lynch, M. Mihm, K. Jung, C. Rhuda, J.C. Schmollinger, F.S. Hodi, L. Liebster, P. Lam, S. Mentzer, S. Singer, K.K. Tanabe, A.B. Cosimi, R. Duda, A. Sober, A. Bhan, J. Daley, D. Neuberg, G. Parry, J. Rokovich, L. Richards, J. Drayer, A. Berns, S. Clift, L.K. Cohen, R.C. Mulligan and G. Dranoff, Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA. 95: 13141-13146, 1998.
67. J.B. Vermorken, A.M. Claessen, H. van Tinteren, H.E. Gall, R. Ezinga, S. Meijer, R.J. Scheper, C.J. Meijer, E. Bloemena, J.H. Ransom, M.G. Hanna, Jr., and H.M. Pinedo, Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial. Lancet, 353: 345-350, 1999.
68. M.B. Nielsen and F.M. Marincola, Melanoma vaccines: The paradox of T cell activation without clinical response. Cancer Chemother. Pharmacol., 46: S62-66, 2000.
69. P. DeMatos, Z. Abdel-Wahab, C. Vervaert, D. Hester, and H. Seigler, Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. J. Surg. Oncol., 68: 79-91, 1998.
70. I.F. Hermans, A. Daish, P. Moroni-Rawson, and F. Ronchese, Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge. Cancer Immunol. Immunother., 44: 341-347, 1997.
71. P. Paglia, C. Chiodoni, M. Rodolfo, and M.P. Colombo, Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med., 183: 317-322, 1996.
72. R.E. Toes, R.J. Blom, E. van der Voort, R. Offringa, C.J. Melief, and W.M. Kast, Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res., 56: 3782-3787, 1996.
73. R.K. Jain, Barriers to drug delivery in solid tumors. Sci. Am., 271: 58-65, 1994.
74. C. Uherek, B. Groner, and W. Wels, Chimeric antigen receptors for the retargeting of cytotoxic effector cells. J. Hematother. Stem Cell Res., 10: 523-534, 2001.
75. R.E. Bird, K.D. Hardman, J.W. Jacobson, S. Johnson, B.M. Kaufman, S.M. Lee, T. Lee, S.H. Pope, G.S. Riordan, and M. Whitlow, Single-chain antigen-binding proteins. Science, 242: 423-426, 1988.
76. J.S. Huston, D. Levinson, M. Mudgett-Hunter, M.S. Tai, J. Novotny, M.N. Margolies, R.J. Ridge, R.E. Bruccoleri, E. Haber, R. Crea, and H. Opperman. Protein engineering of antibody binding sites: Recovery of specific activity in an antidigoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA, 85: 5879-5883, 1988.
77. D. Moritz and B. Groner, A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther., 2: 539-546, 1995.
78. Z. Eshhar, Tumor-specific T-bodies: Towards clinical application. Cancer Immunol. Immunother., 45: 131-136, 1997.
79. D. Mezzanzanica, S. Canevari, A. Mazzoni, M. Figini, M.I. Colnaghi, T. Waks, D.G. Schindler, and Z. Eshhar, Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells. Cancer Gene Ther., 5: 401-407, 1998.
80. C.O. Yun, K.F. Nolan, E.J. Beecham, R.A. Reisfeld, and R.P. Junghans, Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia, 2: 449-459, 2000.
81. P. Hwu, J.C. Yang, R. Cowherd, J. Treisman, G.E. Shafer, Z. Eshhar, and S.A. Rosenberg, In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res., 55: 3369-3373, 1995.
82. N.M. Haynes, M.B. Snook, J.A. Trapani, L. Cerruti, S.M. Jane, M.J. Smyth, and P.K. Darcy, Redirecting mouse CTL against colon carcinoma: Superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. J. Immunol., 166: 182-187, 2001.
83. A. Hombach, C. Schneider, D. Sent, D. Koch, R.A. Willemsen, V. Diehl, W. Kruis, R.L. Bolhuis, C. Pohl, and H. Abken, An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood T cells to specific lysis of carcinoembryonic antigen-positive tumor cells. Int. J. Cancer., 88: 115-120, 2000.
84. D. Moritz, W. Wels, J. Mattern, and B. Groner, Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc. Natl. Acad. Sci. USA, 91: 4318-4322, 1994.
85. I. Stancovski, D.G. Schindler, T. Waks, Y. Yarden, M. Sela, and Z. Eshhar, Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J. Immunol., 151: 6577-6582, 1993.
86. H. Abken, A. Hombach, C. Heuser, and U. Reinhold, A novel strategy in the elimination of disseminated melanoma cells: Chimeric receptors endow T cells with tumor specificity. Recent Results Cancer Res., 158: 249-264, 2001.
87. U. Reinhold, L. Liu, H.C. Ludtke-Handjery, C. Heuser, A. Hombach, X. Wang, W. Tilgen, S. Ferrone, and H. Abken, Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor. J. Invest. Dermatol., 112: 744-750, 1999.
88. R.A. Willemsen, M.E. Weijtens, C. Ronteltap, Z. Eshhar, J.W. Gratama, P. Chames, and R.L. Bolhuis, Grafting primary human T lymphocytes with cancer-specific chimeric single chain and two chain TCR. Gene Ther., 7: 1369-1377, 2000.
89. N. Bach, T. Waks, and Z. Eshhar, Specific lysis of tumor cells by a natural-killer-like cell line transfected with chimeric receptor genes. Tumor Targetting, 1: 203-209, 1995.
90. A. Aruga, K. Yamauchi, K. Takasaki, T. Furukawa, and F. Hanyu, Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization. Int. J. Cancer., 49: 19-24, 1991.
91. D.J. Cole, D.P. Weil, J. Shilyansky, M. Custer, Y. Kawakami, S.A. Rosenberg, and M.I. Nishimura, Characterization of the functional specificity of a cloned T-cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res., 55: 748-752, 1995.
92. S.S. Hom, S.A. Rosenberg, and S.L. Topalian, Specific immune recognition of autologous tumor by lymphocytes infiltrating colon carcinomas: Analysis by cytokine secretion. Cancer Immunol. Immunother., 36: 1-8, 1993.
93. C.G. Ioannides, B. Fisk, B. Tomasovic, R. Pandita, B.B. Aggarwal, and R.S. Freedman, Induction of interleukin-2 receptor by tumor necrosis factor alpha on cultured ovarian tumor-associated lymphocytes. Cancer Immunol. Immunother., 35: 83-91, 1992.
94. D.J. Schwartzentruber, D. Solomon, S.A. Rosenberg, and S.L. Topalian, Characterization of lymphocytes infiltrating human breast cancer: Specific immune reactivity detected by measuring cytokine secretion. J. Immunother., 12: 1-12, 1992.
95. D.J. Schwartzentruber, M. Stetler-Stevenson, S.A. Rosenberg, and S.L. Topalian, Tumor-infiltrating lymphocytes derived from select B-cell lymphomas secrete granulocyte-macrophage colony-stimulating factor and tumor necrosis factor-alpha in response to autologous tumor stimulation. Blood, 82: 1204-1211, 1993.
96. Z.A. Wahab and R.S. Metzgar, Human cytotoxic lymphocytes reactive with pancreatic adenocarcinoma cells. Pancreas, 6: 307-317, 1991.
97. T.L. Whiteside, L.M. Jost, and R.B. Herberman, Tumor-infiltrating lymphocytes. Potential and limitations to their use for cancer therapy. Crit. Rev. Oncol. Hematol., 12: 25-47, 1992.
98. D. Brandle, F. Brasseur, P. Weynants, T. Boon, and B. Van den Eynde, A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med., 183: 2501-2508, 1996.
99. B. Gaugler, N. Brouwenstijn, V. Vantomme, J.P. Szikora, C.W. Van der Spek, J.J. Patard, T. Boon, P. Schrier, and B.J. Van den Eynde, A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics, 44: 323-330, 1996.
100. S. Mandruzzato, F. Brasseur, G. Andry, T. Boon, and P. van der Bruggen, A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med., 186: 785-793, 1997.
101. P.F. Robbins and Y. Kawakami, Human tumor antigens recognized by T cells. Curr. Opin. Immunol., 8: 628-636, 1996.
102. J. Shilyansky, M.I. Nishimura, J.R. Yannelli, Y. Kawakami, L.S. Jacknin, P. Charmley, and S.A. Rosenberg, T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines. Proc. Natl. Acad. Sci. USA, 91: 2829-2833, 1994.
103. A.W. Goldrath, and M.J. Bevan, Selecting and maintaining a diverse T-cell repertoire. Nature, 402: 255-262, 1999.
104. D.J. Cole, D.P. Weil, P. Shamamian, L. Rivoltini, Y. Kawakami, S. Topalian, C. Jennings, S. Eliyahu, S.A. Rosenberg, and M.I. Nishimura, Identification of MART-1-specific T-cell receptors: T cells utilizing distinct T-cell receptor variable and joining regions recognize the same tumor epitope. Cancer Res., 54: 5265-5268, 1994.
105. T. Imanishi, A. Tatsuya, A. Kimura, K. Tikungag, and T. Gojobori, Allele and haplotype frequencies for HLA and complement loci in various ethnic groups, In K. Tsuji, M. Aizawa, T. Saszuki, (Eds.). HLA 1991. Oxford, New York, Tokoyo: Oxford Science Publications, 1994.
106. T.M. Clay, M.C. Custer, M.D. McKee, M. Parkhurst, P.F. Robbins, K. Kerstann, J. Wunderlich, S.A. Rosenberg, and M. I. Nishimura, Changes in the fine specificity of gp100(209-217)-reactive T cells in patients following vaccination with a peptide modified at an HLA-A2.1 anchor residue. J. Immunol., 162: 1749-1755, 1999.
107. I. Riviere, H.F. Gallardo, A.B. Hagani, and M. Sadelain, Retroviral-mediated gene transfer in primary murine and human T-lymphocytes. Mol. Biotechnol., 15: 133-142, 2000.
108. J. Treisman, P. Hwu, S. Minamoto, G.E. Shafer, R. Cowherd, R.A. Morgan, and S.A. Rosenberg, Interleukin-2-transduced lymphocytes grow in an autocrine fashion and remain responsive to antigen. Blood, 85: 139-145, 1995.
109. D. Markowitz, S. Goff, and A. Bank, A safe packaging line for gene transfer: Separating viral genes on two different plasmids. J. Virol., 62: 1120-1124, 1988.
110. A.D. Miller and C. Buttimore, Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol., 6: 2895-2902, 1986.
111. A.D. Miller, J.V. Garcia, N. von Suhr, C.M. Lynch, C. Wilson, and M.V. Eiden, Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J. Virol., 65: 2220-2224, 1991.
112. A. Calogero, G.A. Hospers, K.M. Kruse, P.I. Schrier, N.H. Mulder, E. Hooijberg, and L.F. de Leij, Retargeting of a T cell line by anti MAGE-3/HLA-A2 alpha beta TCR gene transfer. Anticancer Res., 20: 1793-1799, 2000.
113. A. Rao, C. Luo, and P.G. Hogan, Transcription factors of the NFAT family: Regulation and function. Ann. Rev. Immunol., 15: 707-747, 1997.
114. D.G. Miller, M.A. Adam, and A.D. Miller, Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell Biol., 10: 4239-4242, 1990.
115. R.J. Orentas, S.J. Roskopf, G.P. Nolan, and M.I. Nishimura, Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. Clin. Immunol., 98: 220-228, 2001.
116. S.P. Lee, W.A. Thomas, N.W. Blake, and A.B. Rickinson, Transporter (TAP)-independent processing of a multiple membrane-spanning protein, the Epstein-Barr virus latent membrane protein 2. Eur. J. Immunol., 26: 1875-1883, 1996.
117. L.J. Cooper, M. Kalos, D.A. Lewinsohn, S.R. Riddell, and P.D. Greenberg, Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J. Virol., 74: 8207-8212, 2000.
118. H.W.G. Kessels, M.C. Wolkers, M.D. Van den Boom, M.A. Van der Valk, and T.N.M. Schumacher, Immunotherapy through TCR gene transfer. Nat. Immunol., 2: 957-961, 2001.
119. D.B. Woods and K.H. Vousden, Regulation of p53 function. Exp. Cell. Res., 264: 56-66, 2001.
120. T. Stanislawski, R.H. Voss, C. Lotz, E. Sadovnikova, R.A. Willemsen, J. Kuball, T. Ruppert, R.L. Bolhius, C.J. Melief, C. Huber, H.J. Strauss, and M. Theobald, Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol., 2: 962-970, 2001.